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Abstract
The de novo synthesis of glycerolipids in mammalian cells begins with the acylation of glycerol-3-phosphate, catalyzed by
glycerol-3-phosphate acyltransferase (GPAT). GPAT2 is a mitochondrial isoform primarily expressed in testis under
physiological conditions. Because it is aberrantly expressed in multiple myeloma, it has been proposed as a novel cancer
testis gene. Using a bioinformatics approach, we found that GPAT2 is highly expressed in melanoma, lung, prostate and
breast cancer, and we validated GPAT2 expression at the protein level in breast cancer by immunohistochemistry. In this
case GPAT2 expression correlated with a higher histological grade. 5-Aza-29 deoxycytidine treatment of human cells lines
induced GPAT2 expression suggesting epigenetic regulation of gene expression. In order to evaluate the contribution of
GPAT2 to the tumor phenotype, we silenced its expression in MDA-MB-231 cells. GPAT2 knockdown diminished cell
proliferation, anchorage independent growth, migration and tumorigenicity, and increased staurosporine-induced
apoptosis. In contrast, GPAT2 over-expression increased cell proliferation rate and resistance to staurosporine-induced
apoptosis. To understand the functional role of GPAT2, we performed a co-expression analysis in mouse and human testis
and found a significant association with semantic terms involved in cell cycle, DNA integrity maintenance, piRNA biogenesis
and epigenetic regulation. Overall, these results indicate the GPAT2 would be directly associated with the control of cell
proliferation. In conclusion, we confirm GPAT2 as a cancer testis gene and that its expression contributes to the tumor
phenotype of MDA-MB-231 cells.
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Introduction
The de novo synthesis of glycerolipids in mammalian cells begins
with the acylation of glycerol-3-phosphate, catalyzed by glycerol-
3-phosphate acyltransferase (GPAT) [1]. As occurs in many other
lipid metabolic reactions, several isoforms catalyze this step. At
least four different genes encode for GPAT isoforms 1–4, which
differ in tissue expression pattern, subcellular localization, fatty
acyl-CoA substrate preference, and sensitivity to N-ethylmalei-
mide. GPAT1 and GPAT2 are mitochondrial isoforms, whereas
GPAT3 and GPAT4 are localized in the endoplasmic reticulum
[2]. While GPAT1, GPAT3 and GPAT4 are expressed in
lipogenic tissues and their activities are associated with triacylgly-
cerol and phospholipid synthesis, the expression pattern of GPAT2
is more prominent in testis [3]. GPAT2, which is expressed in the
germ line cells in mouse and rat testis, is highly selective for
arachidonoyl-CoA as a substrate [4]. The Gpat2 gene is
transcribed only in primary spermatocytes and the level of both
mRNA and protein decreases in subsequent steps of the
spermatogenic cycle. The function of GPAT2 in male reproduc-
tion remains unknown, but a recent publication showed that
GPAT2 is essential for the biogenesis of piRNA which maintains
genome integrity in germ line cells [5].
Based on a study of multiple myeloma, GPAT2 was proposed to
be a novel ‘‘cancer-testis’’ gene (CT gene) candidate [6]. CT genes
encode proteins whose expression is restricted to male germ cells
and to several tumors of different histological origins, but CT gene
products are absent or expressed at a low level in normal somatic
cells [7]. Their expression is usually regulated by epigenetic
mechanisms, and they are immunogenic. Due to their immuno-
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genic properties, growing lists of CT antigens are being considered
as targets for cancer vaccines [8]. However, little is known about
the function of CT gene products in either spermatogenic or
malignant cells.
The aim of this study was to determine whether GPAT2
behaves as a CT gene and to evaluate the phenotypic consequence
of GPAT2 expression in cancer cells. We chose the MDA-MB-231
cell line derived from human breast carcinoma because these cells
express high levels of GPAT2. GPAT2 gene knockdown in this
cancer cell model showed that GPAT2 can promote cell
tumorigenicity, proliferation and survival.
Experimental Procedures
Ethics Statement
The studies performed with nude mice were approved by the
Directive Board of the INIBIOLP and were carried out in
accordance with the AVMA Animal Welfare Policies (http://
www.avma.org/issues/animal_welfare/policies.asp) and AVMA
Guidelines on Euthanasia (http://www.avma.org/issues/
animal_welfare/euthanasia.pdf). (INIBIOLP’s Animal Welfare
Assurance No. A5647–01).
Cell lines. Human breast adenocarcinoma MDA-MB-231
and colorectal adenocarcinoma HCT116 cells were purchased
from the American Type Culture Collection [9] (Manassas, VA,
USA). Stable cell lines expressing a small-hairpin RNA targeting
GPAT2 mRNA (shRNA-GPAT2) and a non-silencing scrambled
RNA (shRNA-scr) were obtained in our laboratory on the
commercial MDA-MB-231 and HCT116 cell lines using routine
techniques as described below.
Bioinformatics analysis
1. Transcriptional profile of GPAT2 in human normal tissues
and cancer cell lines: to evaluate GPAT2 mRNA expression in
human normal tissues, we analyzed a genome wide gene
expression profile of 677 samples (InSilicoDB, GSE7307). This
data set comprises normal and diseased tissues and cell lines.
Therefore, samples of diseased tissues and cell lines were excluded
from the analysis. In addition, to obtain a more general
representation of the different tissues, we combined those samples
corresponding to different locations of the encephalon (thalamus,
midbrain, caudate, etc.) under the single category designated as
‘‘brain.’’ We also consolidated samples with synonymous names,
such as breast and mammary gland and omitted tissues
represented by just a single sample. A filtered dataset of 36
normal human tissues was used.
In the search for an in vitro model in which to study the role of
GPAT2 in cancerous cells, we assessed the mRNA expression of
GPAT2 in a dataset of 174 samples from 59 cell lines from 9
different cancer tissues. (InSIlicoDB, GSE32474).
2. Transcriptional profile of GPAT2 across human tumor
samples: to perform a comparative analysis of GPAT2 mRNA
expression in different human cancers, we combined ten
independent oligo-microarray studies available in a public
database. To generate a homogeneous dataset, the frozen robust
multiarray analysis (fRMA) preprocessed expression matrixes of
the studies GSE37642 (Acute myeloid leukemia, AML), GSE7553
(primary melanoma, metastatic melanoma, squamous and basal
cell carcinomas), GSE31684 (bladder carcinoma), GSE9843
(hepatocellular carcinoma), GSE18842 (lung cancer), GSE14333
(colorectal cancer), GSE21653 (breast cancer), GSE20685 (breast
cancer), GSE17591 (prostate cancer), and GSE39671 (chronic
lymphocytic leukemia, CLL) were downloaded from the InSilico
database (http://insilico.ulb.ac.be/) [10]. These gene expression
profiles were all developed with the Affymetrix HG U133 Plus2
platform (GPL570). Only tumor samples were considered and
control and/or normal samples present in some datasets were
excluded. The frozen Robust Multiarray Analysis (fRMA) pre-
processing algorithm allows analysis of independent oligo-micro-
array studies/batches, and then combines the data for further
statistical analysis [11]. Our final compiled gene expression data
were 1693 cancer samples. Expression values for GPAT2 were
ordered increasingly, and divided into 3-quantile distribution,
identifying three groups in terms of expression levels: low,
moderate and high. Quantiles are points taken at regular intervals
from the cumulative distribution function of a random variable.
The 3-quantiles are called terciles. In this way, one-third of all the
ranked observations are smaller than the first tercile (this category
was termed low), one-third lie between the first and second tercile
(this category was termed moderate), and one-third are larger than
the second tercile (this category was termed high).
3. GPAT2 co-expression analysis in testis: to further analyze
functional pathways associated with GPAT2, we employed the
‘Guilt by association’ principle, which states that gene co-
expression might indicate shared regulatory mechanisms and roles
in related biological processes [12]. Because GPAT2 resides
principally in testis tissue, co-expressed genes in mouse and human
testis were obtained by using the web-based bioinformatics tool
Multiexperiment Matrix (MEM) http://biit.cs.ut.ee/mem/ [13].
We selected the 300-best positively correlated genes (p,0.0001)
and performed the functional enrichment analysis using the
DAVID [14] and REVIGO [15] tools.
Cell lines and culture conditions
The human MDA-MB-231, HeLa, HEK293, MCF7 and
HCT116 cell lines, derived from mammary adenocarcinoma,
cervix adenocarcinoma, embryonic kidney and colorectal adeno-
carcinoma, respectively, and the normal monkey kidney Vero cell
line were purchased from ATCC and maintained in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin and 2 mM glutamine. Cells were grown at 37uC in a
5% CO2 atmosphere with 98% relative humidity.
GPAT2 silencing
For human GPAT2 silencing, MDA-MB-231 and HCT116
cells were transfected using Lipofectamine 2000 Reagent (Life
Technologies) with HuSH-29 plasmid (OriGene) coding for
shRNA against human GPAT2 mRNA, and selected for
puromycin resistance to generate the respective shRNA-GPAT2
cell line. A non-effective scrambled sequence shRNA plasmid was
used to create a negative control for each cell line (shRNA-Scr).
Both plasmids also contain a sequence coding for green fluorescent
protein driven by a CMV promoter. GPAT2 knock down was
assessed by QPCR.
Quantitative Real-time PCR
Total RNA was isolated from cell lines using TRIZOL (Life
Technologies) following the manufacturer’s instructions, and 1 mg
RNA was used for cDNA synthesis employing High Capacity
Reverse Transcription Kit (Applied Biosystems). A 1/10 cDNA
dilution was used for the QPCR reaction with IQ Sybr Green
Super Mix (Bio-Rad). Primers were designed to amplify a
fragment between exon 15 (forward primer: ATCC-
TACTGCTGCTGCACCT) and exon 17 (reverse primer ACAG-
CAGCTTTGCACTCAGA) of human GPAT2. The thermal
profile was 50uC for 10 min, 95uC for 5 min, followed by 40 cycles
of 95uC for 30 s, 60uC for 1 min and 72uC for 30 s, on a
Stratagene Mx3000P apparatus. RNA expression of the gene of
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interest was quantified in triplicate using the DCt method, and
normalized to that of TBP and b-actin housekeeping genes using
Qbase software.
Cell proliferation, soft agar growth and wound healing
assays
Cell proliferation rates were assessed by reduction of MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) re-
agent [16]. Six-thousand cells were seeded in 12-well plates and
cultured for 72 h. Viability was estimated at different time points.
Briefly, 50 ml of MTT stock solution (5 mg/ml in PBS, pH 7.5)
was added to each well at the indicated time points and incubated
for 4 h at 37uC in the darkness. Then, 500 ml of solubilizing
solution (0.04 M HCl in isopropanol) was added and incubated for
20 minutes at RT. Plates were read at 560 nm, and 640 nm for
background subtraction, in a Beckman Coulter - Multimode
microplate reader DTX-880.
For soft agar assay, a base layer of 1.5 ml of the corresponding
culture media containing 0.5% agarose and 10% FBS was added
to 35-mm plates. After the base layer was solidified, 5000 cells
were resuspended in 1.5 ml of culture media containing 0.35%
agarose and 10% FBS and added to the plates. Plates were
incubated at 37uC in a humidified incubator for 14 d. Colonies
were visualized and counted under florescence microcopy in an
inverted microscope (Olympus, IX71).
For wound healing assay, cells were grown to confluence on
10 mm plates and wounded six times in the cell monolayer with a
200-ml standard pipette tip. Cells were then washed twice with
PBS to remove cell debris and incubated with routine conditions.
Images of the area of cell-free wounds were captured at 0, 2, 6 and
8 h. using an inverted microscope (Olympus, IX71) equipped with
a digital camera (Olympus) under 1006 magnification. To
quantify the migration rate of the cells, the wound width was
measured at ten different regions for each wound at each time
point, and the mean and standard deviation were calculated.
Apoptosis assay
Cells were seeded in triplicate on coverslips placed into 6-well
plates and allowed to grow until the cell density reached 2.56105
cells per well (60% confluence). A 1 mM stock solution of
staurosporin (STS) was prepared in DMSO, and added to the
culture medium to give 1 mM STS final concentration. The
cultures were subsequently incubated for different time periods.
Terminal deoxynucleotidyl transferase-mediated dUTP (29-deox-
yuridine 59-triphosphate)-digoxigenin nick end labeling (TUNEL)
assay was performed on culture cells using the In Situ Cell Death
Detection Kit (Roche), according to the manufacturer’s instruc-
tions. Finally, coverslips were mounted on slides and stained with
haemotoxylin. The percentage of apoptotic cells was calculated by
determining the number of TUNEL positive cells in 10 randomly
selected 60X fields using an optical microscope (Nikon, E100).
GPAT2 overexpression
Human GPAT2 was stably overexpressed in MDA-MB-231
cells. To obtain stable cell lines, MDA-MB-231 cells were grown in
60-mm dishes to 90% confluence and then transfected with 5 mg
of the cDNA encoding the complete open reading frame of human
GPAT2 cloned in the pCMV6 vector (TrueORF, Origene) or with
the empty vector as control. Both plasmids also contain a sequence
coding for green fluorescent protein driven by an IRE translational
element. Cells were transfected using Lipofectamine 2000 and
then selected with Geneticin (Life Technologies) to establish
pCMV6-GPAT2 (GPAT2-overexpressing) and pCMV6 (control)
cells, which were used for MTT and TUNEL assays as described
above.
Murine Gpat2 was transiently overexpressed in HeLa, Vero and
HEK293 cells. Eight-thousand cells/well were seeded in 48MW
plates and 24 h later cells were transfected with 0.6 mg/well of the
cDNA encoding the complete ORF of murine Gpat2 cloned into
pcDNA3.1 vector (pcDNA3.1-Gpat2) or the empty pcDNA3.1
vector as previously reported [4]. Forty-eight h later, cell density
was assessed by crystal violet staining [16]. GPAT2 and Gpat2
overexpression was monitored by qPCR.
Immunohistochemistry
To examine the expression of GPAT2 protein in human breast
cancer tissue, we performed immunohistochemistry on a tissue
microarray (TMA) of human breast cancers (n = 36) or normal
tissue (n = 6) (Origene, CT565863). Endogenous peroxidase was
inactivated by 1% H2O2 in methanol for 30 min. The slide was
then washed three times with 1X PBS and blocked with 10%
normal horse serum in 1% bovine serum albumin (Sigma) in 1X
PBS for 1 h. The antigen retrieval was performed immersing the
slide in 10 mM citrate buffer (pH 6) at 100uC for 5 min. After
washing three times with PBS, the slide was incubated with rabbit
anti-human GPAT2 (Sigma HPA036841) polyclonal antibody
(1:35) overnight at 4uC in a humidified chamber. Then, secondary
HRP-conjugated anti-rabbit immunoglobulin diluted in the
blocking solution (1:150; Thermo-Pierce) was added for 1 h at
room temperature. The reaction was developed with the LSAB2/
HRP kit and liquid 3,39-diaminobenzidine (Dako) according to the
manufacturer’s recommendations. Slides were counter-stained
with haematoxylin to visualize the nuclei and analyzed with an
Olympus BX52 microscope.
5-aza-29-deoxycytidine (DAC) treatment
To determine the effect of demethylation on the expression of
the GPAT2 gene, HEK293, HeLa, MCF7 and MDA-MB-231
cells were seeded at low density in six-well plates and treated with
2 mM DAC (Sigma) or DMSO for 96 h. After treatment, RNAs
were isolated and analyzed for GPAT2 expression as described
above.
Athymic nude mice xenografts
Athymic female nude mice (N:NIH(S)-nu/nu/LP, 6 wk-old)
were obtained from Facultad de Ciencias Veterinarias, UNLP (La
Plata, Argentina). After a one-wk acclimation period, mice were
randomly divided into three groups (shRNA-GPAT2, shRNA-Scr
or control; n = 5 per group). Then, 3.26106 shRNA-GPAT2 or
shRNA-Scr cells (suspended in 200 ml DMEM) were inoculated
subcutaneously on the upper back of the mice; the control group
received only the vehicle. Thereafter, mice were monitored daily
for tumor occurrence by visual inspection and palpation. When
detected, tumor growth was monitored twice weekly using calipers,
and tumor volume was calculated using the following formula:
length6width261/2. Twelve wk after cell administration, mice
were euthanized and xenograft tumors were excised and weighed.
Statistical analysis
Statistical comparisons were performed with SPSS statistics 17.0
software. The T-test or ANOVA, and the exact Fisher test were
employed for continuous and discrete variables, respectively.
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Figure 1. In silico analysis of GPAT2 mRNA expression profile. A) In silico analysis of GPAT2 expression profile across human normal tissues. B)
GPAT2 mRNA expression across different tumor localizations was assessed with a bioinformatics approach, and expression level was classified into
low, moderate and high. The percentage of cases in each category (low: light gray, moderate: dark gray, high: black) is displayed in the graph **p,
0.01. C) GPAT2 expression profile across human cancer cell lines.
doi:10.1371/journal.pone.0100896.g001
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Figure 2. Phenotypic consequences of GPAT2 knock down in MDA-MB-231 cells. A) Total RNA was extracted from the MDA-MB-231 parent
cell line, shRNA-Scr and shRNA-GPAT2 cells, subjected to cDNA synthesis and amplified by quantitative RT-PCR using primers for human GPAT2 gene,
normalizing its expression level to that of TBP and b-actin housekeeping genes **p,0.01. B) shRNA-Scr and shRNA-GPAT2 cells were seeded at
10,000 cells/well on MW12 plates and incubated for 24, 48, and 72 h before estimating the cell proliferation rate by MTT proliferation assay *p,0.05.
C) 5,000 cells from shRNA-Scr and shRNA-GPAT2 cells were seeded on 35-mm DMEM-agar plates and the number of colonies was quantified by
fluorescent microscope after 14 d incubation under normal culture conditions ***p,0.001. D) shRNA-Scr and shRNA-GPAT2 cells were grown to
confluence on 10 mm plates and the cell monolayer was wounded six times. The wound width was measured at 0, 2, 6 and 8 h under 1006
magnification and the percentage of wound closure was calculated *p,0.05. E) shRNA-Scr and shRNA-GPAT2 cells were treated with apoptosis
inducer staurosporine for 30 min or 2 h and the percentage of apoptotic cells was determined by counting the number of apoptotic and non-
apoptotic cells using TUNEL assay and haematoxylin staining **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0100896.g002
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Results
GPAT2 is highly expressed in human testis and several
cancer types
Because GPAT2 has been proposed to be a novel CT gene and
in order to validate its high expression in human testis and in
cancers, we performed an in silico analysis of GPAT2 mRNA
expression. First, we evaluated the gene expression profile in 36
different normal human tissues and confirmed that the highest
expression of GPAT2 was in testis (p,0.01, Figure 1A). The
expression profile obtained from this analysis allowed us to classify
GPAT2 expression as ‘‘testis-selective’’ [17].
To determine out which tumor locations express high GPAT2
mRNA levels, we analyzed a compiled dataset of 1693 samples
derived from 13 different cancer types (Figure 1B). According to
GPAT2 expression, samples were divided into three categories: low,
moderate and high as detailed in the previous section. Statistical
analysis revealed that tumor locations with higher percentage of
samples in the ‘‘high GPAT2 expression group’’ (p,0.01) were:
melanoma (44%), lung (41%), prostate (65%), and breast tumor
(42%). On the other hand, renal (55%), colorectal (47%),
hepatocellular (64%), basal cell (67%) and hematological cancers
(AML, 47%; UCSD CLL, 51%) showed a significantly higher
percentage of samples with low expression of GPAT2 (p,0.01). We
also evaluated GPAT2 expression profile in cancer cell lines in order
to get an in vitro model of GPAT2 expressing cell line. Fifty nine cell
lines derived from 9 different cancers were analyzed. GPAT2
showed the highest expression level in the breast cancer cell line
MDA-MB-231, which is characterized as a very aggressive tumor,
because it is highly proliferative and tumorigenic (Figure 1C). This
cell line was therefore chosen as our primary in vitro model to
evaluate the phenotypic consequences of GPAT2 silencing.
GPAT2 promotes cell proliferation, anchorage-
independent growth, migration and survival of MDA-MB-
231 cells
To analyze and compare different phenotypic consequences of
GPAT2 stable silencing on MDA-MB-231, we used RNA
interference technology to knock down GPAT2 expression and
obtained two stable cell lines: MDA-MB-231 that expresses
shRNA targeting GPAT2 (shRNA-GPAT2) and a control
MDA-MB-231 cell line expressing a scrambled shRNA (shRNA-
Scr). A 95% down-regulation of GPAT2 mRNA was obtained for
shRNA-GPAT2, compared to shRNA-Scr cells (p,0.01,
Figure 2A).
The MTT proliferation assay was used to test changes in cell
growth rate. Interestingly, the proliferation rate of the GPAT2
silenced cells was 2-fold lower compared to the scrambled cells
(p,0.01, Figure 2B). We also evaluated the anchorage-indepen-
dent growth capacity, a main feature of malignant transformation,
which measures the proliferation rate in a semisolid culture media.
Silencing of GPAT2 markedly diminished the ability of MDA-
MB-231cells to grow in a semisolid medium; the number of
colonies counted at 14 days was reduced by 90% in shRNA-
GPAT2 vs. shRNA-Scr cells (p,0.001, Figure 2C).
Cell migration was also diminished in the wound healing assay.
The percentage of wound closure was lower in shRNA-GPAT2 vs
shRNA-Scr cells at 6 h (43.3% vs. 68.7%; p,0.01), and 8 h
(51.9% vs. 88.1%; p,0.01) after wound production (Figure 2D).
In order to learn whether GPAT2 silencing alters sensitivity to
apoptosis, we treated shRNA-GPAT2 and shRNA-Scr cells with
the apoptosis inducer STS (1 mM final concentration) for 30 min
and 2 h. The percentage of apoptotic cells was determined by
TUNEL assay (Figure 2E). At 30 min of treatment, apoptosis was
dramatically increased in silenced cells compared to control cells
(85.4% and 6.6%, respectively; p,0.001); this effect was also
evident at 2 h with 96% and 37% mortality, respectively; p,0.01.
The vehicle DMSO did not induce apoptosis in our assay
conditions.
In order to check the phenotypic consequences of GPAT2
silencing in other cancerous cell line, HCT116 was chosen due to
its high GPAT2 expression level (Figure 1C). GPAT2 mRNA was
stably knocked-down by 70% (Figure 3A), and consistent with
MDA-MB-231 cells, shRNA-GPAT2 cell line proliferation rate
was lower than shRNA- Scr cell line (Figure 3B).
These results clearly showed that GPAT2 down regulation
diminished cell proliferation and increased sensitivity to apoptosis
of MDA-MB-231 cells. To test whether GPAT2 overexpression
evokes a reverse phenotype we obtained a stable MDA-MB-231
cell line overexpressing GPAT2 (pCMV6-GPAT2) 8.5-fold higher
Figure 3. GPAT2 knock down in HCT116 cells. A) Total RNA was extracted from the HCT116 parent cell line, shRNA-Scr and shRNA-GPAT2 cells,
subjected to cDNA synthesis and amplified by quantitative RT-PCR using primers for human GPAT2 gene, normalizing its expression level to that of
TBP and b-actin housekeeping genes **p,0.01. B) shRNA-Scr and shRNA-GPAT2 cells were seeded at 5000 cells/well on MW12 plates and incubated
for 24, 48, 72 and 96 h before estimating the cell proliferation rate by MTT proliferation assay ***p,0.001.
doi:10.1371/journal.pone.0100896.g003
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than the empty-vector control. These cells proliferated 2-times
faster than control cells (Figure 4A and B). STS-induced apoptosis
was measured in pCMV6-GPAT2 and pCMV6 cells by TUNEL
assay. When treated with 1 mM STS for 2 h, pCMV6-GPAT2
cells had a lower percentage of apoptotic cells than control cells
(37% vs 44% p,0.01). After 5 h of incubation, 95% of control
cells showed apoptotic traits whereas only 77% of GPAT2
overexpressing cells were affected, (p,0.001, Figure 4C), showing
that pCMV6-GPAT2 cells were more resistant to STS-induced
apoptosis. The effect of GPAT2 expression on cell proliferation
was also evident when cDNA coding for murine Gpat2 was
transiently transfected in different cell lines. Cell proliferation
increased 68%, 100% and 48% when Gpat2 was overexpressed in
HeLa, Vero and HEK293 cells respectively (Figure 4B).
GPAT2 silencing inhibits MDA-MB-231 tumorigenicity in
vivo
Results obtained in vitro led us to evaluate the tumorigenicity of
the MDA-MB-231 shRNA-GPAT2 cells in nude mice. While
100% (5/5) of shRNA-Scr inoculated mice developed tumors,
none of the mice given shRNA-GPAT2 (0/5) generated tumor
xenografts. These results suggest that GPAT2 silencing severely
inhibited the tumorigenicity of MDA-MB-231 cells.
GPAT2 is highly expressed in undifferentiated breast
carcinomas
We showed that GPAT2 expression is required for the high rate
of proliferation, anchorage independent growth, tumorigenicity,
and survival of MDA-MB-231 cells. To analyze GPAT2
expression at the protein level in human breast adenocarcinomas,
we performed immunohistochemistry (using an anti-GPAT2
antibody previously validated in our lab [4]) on a commercial
breast tissue microarray. GPAT2 was not detected in any of the
normal samples (n = 6), but its frequency in carcinomas (n = 35)
was 37% (Figure 5A and B). Similar to its subcellular localization
in normal testicular germ cells, GPAT2 showed immunoreactivity
in the cytoplasm of cancerous cells (Figure 5A, middle panel).
When the histopathological variables were analyzed, a significant
Figure 4. Phenotipic consequences of human and murine GPAT2 overexpression. A) Total RNA from pCMV6 and pCMV6-GPAT2 cells was
extracted, subjected to cDNA synthesis and amplified by quantitative RT-PCR using primers for human GPAT2 gene, normalizing its expression level
to that of TBP and b-actin housekeeping genes *** p,0.001. B) pCMV6 and pCMV6-GPAT2 cells were seeded at 10,000 cells/well on MW12 plates and
incubated for 24, and 48 h before estimating the cell proliferation rate by MTT proliferation assay ***p,0.001. C) pCMV6 and pCMV6-GPAT2 cells
were seeded in coverslips and 24 h later apoptosis was induced by 1 mM staurosporine treatment for 2 and 5 h. The percentage of apoptotic cells
was determined by counting the number of apoptotic and non-apoptotic cells using TUNEL assay and haematoxylin staining **p,0.01; ***p,0.001.
D) pcDNA3.1 (empty vector) and the cDNA coding for mouse Gpat2 cloned in pcDNA3.1 (pcDNA3.1-Gpat2) were transiently transfected in HeLa, Vero
and HEK293 cells. Cell density was estimated 48 h post-transfection by crystal violet assay. ***p,0.001.
doi:10.1371/journal.pone.0100896.g004
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positive association with the histological grade was obtained. Only
11% of Grade I/II tumor samples were positive for GPAT2
protein expression, compared to 55% for Grade III samples (p,
0.05) (Figure 5C).
GPAT2 expression is upregulated by DAC treatment
Epigenetic regulation is a hallmark of cancer testis gene
expression [18]. To assess whether GPAT2 expression is regulated
by DNA methylation, we treated HEK293, HeLa, MCF7 and
MDA-MB-231 cell lines with the methyltransferase inhibitor DAC
Figure 5. GPAT2 protein expression in human breast carcinomas. GPAT2 protein expression in human breast tissues was assayed on a tissue
microarray (TMA) by immunohistochemistry. A) Representative samples of normal breast (left panel), breast adenocarcinoma positive for GPAT2
stainning (GPAT2 (+)) (middle panel) and breast adenocarcinoma negative for GPAT2 staining (GPAT2(-)) (right panel) are displayed. GPAT2
expression was detected by peroxidase reaction (brown signal, arrows) and nuclei were counterstained with haematoxilin (blue stain). Magnification:
2006, 6006and 10006. Statistical analysis of GPAT2 protein expression on the TMA: B) frequency of GPAT2 expression between normal breast and
breast adenocarcinoma (carcinoma) and C) frequency of GPAT2 expression in adenocarcinoma (carcinoma) samples according to their histological
grade (Nottingham scale).
doi:10.1371/journal.pone.0100896.g005
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at 2 mM for 96 h or with DMSO as a control. The expression of
GPAT2 was low in HEK293, HeLa and MCF7 cells compared to
MDA-MB-231 cells (Figure 6A). DAC treatment was able to
significantly increase GPAT2 expression in HEK293, HeLa and
MCF7 cells, but had no effect on MDA-MB-231 cells (Figure 6B).
This result strongly suggests that GPAT2 expression is epigenet-
ically regulated.
In silico co-expression analysis indicates that GPAT2
would be associated with piRNA metabolism and cell
cycle control pathways
Based on our experimental results and to identify the functional
role of GPAT2, we performed a co-expression analysis in mouse
and human testis. The top 300 best correlated genes (p,0.001)
were selected for functional analysis. A visual summary of no
redundant gene ontology terms was obtained by using DAVID
and REVIGO bioinformatics tools. Remarkably, similar gene
ontology terms were identified in mouse and human analyses
(Figure 7). In both species, two clusters involving gene ontology
terms connections were evident. One of these clusters, contained
general terms like sexual reproduction and gamete generation, and
included cell cycle-related gene ontology terms, like cell division,
cell proliferation, cell cycle process, regulation of cell cycle and
chromosome segregation. The other cluster was related to DNA
metabolism including gene ontology terms like DNA methylation,
regulation of gene expression, epigenetic, RNA biosynthesis, DNA
modification and piRNA metabolism. Among the co-expressed
genes with human GPAT2 included 18 CT genes, reinforcing the
idea that GPAT2 behaves as CT gene.
Discussion
The main finding of this study is that GPAT2 does not behave
as a ‘‘classical’’ GPAT and its expression is linked to malignancy
rather than to glycerolipid synthesis. We have previously reported
in mice and rats that GPAT2 expression and activity is unrelated
to the other three isoforms [4].
Human GPAT2 has been proposed as a novel CT gene
candidate [6] based only on the fact that GPAT2 mRNA
expression profile was selective to the testis and to myeloma cells.
In order to validate this hypothesis, we have taken both in silico and
experimental approaches to confirm that GPAT2 meets the
Figure 6. Effect of DAC treatment on mRNA GPAT2 expression in human cell lines. A) Relative mRNA expression of GPAT2 in human cell
lines was assayed by quantitative RT-PCR. B) MCF7, HeLa, HEK-293 and MDA-MB-231 cells were treated with the methyltransferase inhibitor 5-aza-29-
deoxycitidyne 2 mM for 96 h (DAC) or with DMSO (control), and the mRNA relative expression of GPAT2 gene was assessed by quantitative RT-PCR.
**p,0.01.
doi:10.1371/journal.pone.0100896.g006
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criteria of a CT gene. We explored GPAT2 distribution in
different cancer tissues, we detected GPAT2 expression at protein
level in cancer cells and we obtained evidence that GPAT2
expression is epigenetically regulated.
One of the main features of CT genes is that they are expressed
not only in testis but also in tumors. In this sense, tumors have
been classified in high, moderate or low CT gene expressers [19].
Using data available in public databases, we analyzed the GPAT2
expression profile in human tumor samples and found that in each
tumor location only a fraction showed high GPAT2 expression
levels. The locations in which there was a statistically higher
proportion of samples with ‘‘high expression’’ were lung,
melanoma, breast, and prostate cancer, whereas ‘‘low expression’’
was most frequent in renal, colorectal, and hepatocellular cancers
and in hematopoietic malignancies. This expression pattern in
different tumors is consistent with the distribution of other CT
genes in human cancers [19]. Although the number of CT genes
identified has been increasing, knowledge of the expression pattern
at the protein level is still limited. In this study, we explored
GPAT2 protein expression in breast carcinoma tissues, and found
that 36% of breast tumors express this protein. This frequency is
relatively high compared to reported frequencies for other CT
genes in breast cancer [19]. Additionally, when histopathological
variables were analyzed, GPAT2 showed a positive association
with the histological grade, which is also characteristic of CT
genes, since they are preferentially expressed in high grade breast
cancers [8,20].
Another hallmark of CT genes is epigenetic regulation. CT
genes have methylated promoters in normal non-expressing
somatic tissues and are activated by demethylation during
spermatogenesis and carcinogenesis [18,20]. DAC treatment of
human cell lines expressing GPAT2 at very low levels evoked a
very strong induction of gene expression, whereas the same
treatment had no effect on MDA-MB-231 cells, which normally
express GPAT2. These results allowed us to conclude that
methylation/demethylation is a mechanism governing GPAT2
expression.
One key question about CT genes is whether their expression
contributes to the tumor phenotype. To address this, we stably
knocked-down GPAT2 in MDA-MB-231 cells. Gene abrogation
dramatically decreased cell proliferation, anchorage independent
growth and migration of MDA-MB-231 cells, features that are all
related to tumor progression. GPAT2 silencing also diminished
cell proliferation of HCT116 cells and both murine and human
GPAT2 overexpression increased cell proliferation. These results
agree with experiments reporting either siRNA-mediated silencing
or overexpression of specific CT genes, which demonstrate
causality between CT gene expression and growth phenotype
[21–25]. The dramatic reduction of the MDA-MB-231 tumor
phenotype by GPAT2 silencing was also evident in vivo, because
knocked down cells were unable to generate tumor xenografts in
nude mice. The contribution of GPAT2 to malignancy appears to
be not only restricted to an increased cell proliferation, because
GPAT2 silenced cells were more sensitive to STS induced
apoptosis and GPAT2 overexpressing cells were more resistant
to STS induced apoptosis.
Our results, as well as those reported from other groups, support
the idea that ectopic CT gene expression in somatic cells promotes
tumorigenesis. The mechanisms by which each CT gene
contributes to a tumor phenotype are poorly understood but
revealing CT gene function in spermatogenesis could provide
clearer insights into how CT genes act in cancer. For this reason,
we performed a co-expression analysis for GPAT2 in mouse and
human testis, the tissue in which GPAT2 exerts its physiological
role. Two main clusters of ontological terms in both species were
found. One of these clusters was associated with the regulation of
Figure 7. Gene ontology classification of genes co-expressed with GPAT2 in mouse and human testis. Scatterplot graph of the top 300
GPAT2 co-expressed genes showing the representative functional clusters according to gene ontology terms with a statistical significance of p,0.01,
in a two dimensional space related to gene ontology terms’ semantic similarities. Bubble color indicates the p-value of gene ontology terms
(expressed as Log10 p-value), where blue and green bubbles are gene ontology terms with more significant p-values than the orange and red
bubbles. Bubble size indicates the frequency of the gene ontology term in the underlying gene ontology database.7
doi:10.1371/journal.pone.0100896.g007
Association between GPAT2 Expression and Cancer
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e100896
gene expression by epigenetic mechanisms, RNA biosynthesis and
piRNA metabolism, consistent with a report that GPAT2 plays a
critical role in piRNA biogenesis [5]. piRNAs are small non-
coding RNAs synthesized in germ cells, whose accepted function is
to use DNA methylation to repress the expression in germ cells of
deleterious retrotransposons [26]. The relationship between
piRNA metabolism and cancer has been considered. In Drosoph-
ila ectopic expression of piRNA pathway genes are responsible for
the development of brain tumors [27] and specific piRNAs are
aberrantly overexpressed in gastric, colon, lung and breast cancer
tissues [28]. However, the mechanisms of piRNAs involvement in
tumorigenesis are yet to be determined. The second cluster
showed ontological terms associated with cell cycle, such as M
phase, chromosome segregation, centromere complex assembly
and cell proliferation, suggesting a role for GPAT2 in the control
of cell cycle, perhaps through its participation in chromosome
segregation. Whether all these terms are associated with piRNA
metabolism or if they reveal an independent function for GPAT2
must be determined, but a link between piRNA metabolism and
mitosis was recently described [29].
In summary, our co-expression analysis in mouse and human
testis confirm the role of GPAT2 in piRNA metabolism and
suggest an emerging role for GPAT2 in the control of cell cycle,
probably through its participation in chromosome segregation.
Our present data linking GPAT2 to tumorigenesis open the
possibility of considering GPAT2 as a potential target for
treatment of highly aggressive cancers.
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